Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 40,000 shares at $33.40 ($1.4M) on 2022-03-23, disclosed to the SEC on 2022-03-25.
Open-market sale of $1.4M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.40 | 8,402 | $281K | 20.7% |
| 2 | $33.40 | 8,402 | $281K | 20.7% |
| 3 | $34.14 | 11,598 | $396K | 29.3% |
| 4 | $34.14 | 11,598 | $396K | 29.3% |
| Total | $33.83 avg | 40,000 | $1.4M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |